NXTS vs ARGX Stock Comparison

Nexentis Technologies and Argenx Se Prices as of Oct 26, 2026 Peers: Industry group
ARGX Argenx Se
$869.33 -9.4% 1M +6.4% 1Y
Market cap
$53.80B
P/E
28.4x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
5 wins

Head to Head

5 decided of 12

Argenx Se leads on 5 of the 12 questions below (Argenx Se 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSARGXLeader
Larger companyMarket capitalisation $457.04K $53.80B ARGX
Cheaper on earningsLower P/E, profitable companies only 0.0x 28.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 27.8x –
Faster revenue growthRevenue growth, trailing twelve months — +61.5% –
More profitableNet margin, trailing twelve months — 32.3% –
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA 1.6x — –
Higher dividend yieldTrailing dividend yield — — –
Better 1-year returnPrice return, last 12 months -97.9% +6.4% ARGX
Better 5-year returnAnnualised price return, 5 years -86.1%/yr +25.5%/yr ARGX
Less volatileAnnualised volatility, 1 year 169.1% 37.0% ARGX
Higher overall scoreMean of the five percentile scores vs peers 33/100 91/100 ARGX

Percentile Scorecard

NXTSARGX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSARGX
Valuation – 80 #56 of 275
Growth 13 #221 of 253 95 #14 of 253
Profitability 42 #130 of 224 98 #6 of 224
Financial Health 44 #165 of 296 –
Shareholder Returns – –
Overall 33 91
  • NXTS ranked among 305 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 305 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSARGXSPY
1 month -61.9%-9.4% -0.8%
3 months -66.5%-2.2% +3.5%
6 months -88.4%+10.9% +7.0%
Year to date -95.2%+3.4% +12.2%
1 year -97.9%+6.4% +13.0%
3 years -99.9%+89.0% +86.3%
3 years, per year -89.6%+23.7% +23.1%
5 years -100.0%+210.9% +68.6%
5 years, per year -86.1%+25.5% +11.0%
10 years -100.0%— +258.0%
10 years, per year -66.6%— +13.6%

Risk

MeasureNXTSARGXSPY
Volatility, 1Y 169.1%37.0% 12.7%
Downside volatility, 1Y 153.3%34.6% 12.7%
Beta vs S&P 500, 1Y 2.310.39 1.00
Return / volatility, 1Y -0.580.17 1.02
Max drawdown, 5Y -100.0%-38.2% -25.4%
From 52-week high -97.8%-17.9% -1.8%
52-week high $26.04$1,058.90 $779.14
52-week low $0.53$663.93 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSARGX
P/E now vs peer median 0.0xmedian 10.4x 28.4xmedian 10.4x
P/S now vs peer median —median 6.4x 9.2xmedian 6.4x
EV/EBITDA now vs peer median 1.5xmedian 10.7x —median 10.7x
P/FCF now vs peer median —median 12.5x —median 12.5x
P/B now vs peer median 0.2xmedian 1.6x —median 1.6x
PEG now vs peer median 0.00median 0.29 0.27median 0.29

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSARGX
Revenue – $5.82B
Gross profit – $5.24B
Operating income -$5.28M $1.74B
Net income -$14.06M $1.88B
R&D $532.00K $1.80B
EPS (diluted) $-17.10 $28.43
Cash & equivalents $7.62M –
Total debt $3.22M –
Shares (diluted) 816.14K 66.03M
Enterprise value -$22.31M $53.80B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSARGX
P/E 0.0x 28.4x
P/FCF – –
P/Operating cash flow – –
P/S – 9.2x
P/B 0.2x –
P/Tangible book -0.2x –
EV/EBITDA 1.5x –
EV/EBIT 1.5x 30.9x
EV/Revenue – 9.2x
EV/FCF – –
EV/Operating cash flow – –
PEG (3Y EPS CAGR) 0.00 0.27

Growth

14 metrics
MetricNXTSARGX
Revenue growth (1Y) – 61.5%
Revenue CAGR (3Y) – 80.5%
Gross profit growth (1Y) – 62.2%
Gross profit CAGR (3Y) – 80.0%
Operating income growth (1Y) -7.7% 120.6%
Operating income CAGR (3Y) 3.0% 85.1%
Net income growth (1Y) -48.2% 22.5%
Net income CAGR (3Y) -35.8% 115.5%
EPS growth (1Y) -567.8% 20.9%
EPS CAGR (3Y) -45.2% 104.8%
Operating cash flow growth (1Y) – –
Operating cash flow CAGR (3Y) – –
Free cash flow growth (1Y) – –
Free cash flow CAGR (3Y) – –

Profitability

14 metrics
MetricNXTSARGX
Gross margin – 90.0%
EBITDA margin – –
Operating margin – 29.9%
Pretax margin – 32.6%
Net margin – 32.3%
FCF margin – –
Operating cash flow margin – –
Return on equity -157.0% –
Return on assets -71.9% –
Return on invested capital – –
Return on capital employed -31.5% –
Asset turnover – –
Cash conversion (OCF / net income) – –
Stock comp / revenue – –

Financial Health

11 metrics
MetricNXTSARGX
Debt / assets 2.3% –
Debt / equity 0.2x –
Net debt / EBITDA 1.6x –
Debt / FCF – –
Liabilities / assets 89.8% –
Equity / assets 10.2% –
Interest coverage – 10,120x
Current ratio 3.7x –
Quick ratio 3.2x –
Cash ratio 3.2x –
Altman Z-score – –

Shareholder Returns

7 metrics
MetricNXTSARGX
Dividend yield – –
Net buyback yield – –
Shareholder yield – –
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSARGX
Forward P/E – 27.8xFY2026
EPS, next fiscal year – $31.22FY2026
EPS growth, next FY – +59.5%FY2026
EPS growth, the year after – +29.0%
Revenue, next fiscal year – $5.97BFY2026
Revenue growth, next FY – +40.4%FY2026
Revenue growth, the year after – +21.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSARGX
Held by institutions – 46.1%
Institutions holding – 504
Change in shares held, QoQ – -2.0%
Institutions buying – 264
Institutions selling – 160
Buyers to sellers – 1.65

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSARGX
NXTS 1.00 0.12
ARGX 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS and ARGX?

Argenx Se (ARGX) is the largest by market capitalisation: Nexentis Technologies (NXTS) $457.04K, Argenx Se (ARGX) $53.80B.

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Nexentis Technologies (NXTS) -97.9%, Argenx Se (ARGX) +6.4%. Over five years, Argenx Se (ARGX) compounded fastest (Nexentis Technologies (NXTS) -86.1%/yr, Argenx Se (ARGX) +25.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Argenx Se (ARGX) has been the steadiest (Nexentis Technologies (NXTS) 169.1%, Argenx Se (ARGX) 37.0%). Volatility measures how widely the price swings, not the risk of the business.

Do NXTS and ARGX move together?

Their daily returns over the past year have a correlation of 0.12, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, NXTS and ARGX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.